Genscript Biotech Corporation (abbreviated as GENSCRIPT BIO) has circulated the proxy form for its 2026 Annual General Meeting (AGM), confirming the session will take place at 9:30 a.m. on Friday, 5 June 2026 in the company’s Conference Room at No. 1688 Shuanglong Avenue, Jiangning District.

Key items tabled for shareholder approval include:

1. FY-2025 financials • Adoption of the audited consolidated financial statements for the year ended 31 December 2025, together with the reports of the directors and Ernst & Young.

2. Board composition • Separate re-election votes for executive directors Dr. Fangliang Zhang, Mr. Jiange Meng and Dr. Li Zhu. • Re-election of Dr. Chenyang Shi as an independent non-executive director. • Authorisation for the board to determine directors’ remuneration.

3. Auditor • Re-appointment of Ernst & Young as external auditor and authorisation for the board to set its fee.

4. Share capital mandates • General mandate allowing the board to allot, issue and deal with new shares— including any sale or transfer of treasury shares—up to 20 % of the company’s issued share capital (excluding treasury shares) as at the date of approval. • Authority to buy back shares up to 10 % of issued share capital (excluding treasury shares). • Extension of the issuance mandate by the number of shares actually bought back under the repurchase mandate.

5. Corporate governance update • Special resolution to adopt the fifth amended and restated memorandum and articles of association, superseding the current fourth edition.

Shareholders recorded on the register may appoint one or more proxies; completed forms must reach the Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, by 9:30 a.m. on Wednesday, 3 June 2026 (Hong Kong time). Attendance in person remains permissible even after a proxy is lodged.